Molecular Therapy · 2013 · 619 citations · 16 references
PharmacyBiotechnologyPharmaceuticsBiocompatibilityDrug DeliveryNanoparticle Drug DeliveryLipid-based NanoparticlesNanocarriers For TherapeuticsNanomaterials For Drug DeliveryNanomedicineNucleic Acid DeliveryRna InterferenceIonizable LipidsLipid NanocarriersLipid Nanoparticle Delivery SystemsLipid NanoparticlesLipid-based Delivery SystemsNanoparticle DeliveryRna Interference TherapeuticsSystemic Delivery
RNA interference therapeutics delivered by lipid nanoparticles have entered clinical trials, underscoring the importance of ionizable lipids and the ongoing emphasis on biodegradability to improve biocompatibility and clearance. The study aims to develop next‑generation biodegradable lipids that retain the potency of current advanced lipids while adding degradable functionality. The authors synthesized a new class of biodegradable lipids for lipid nanoparticles and evaluated their plasma and tissue clearance, tolerability, and in‑vivo potency. The representative lipid exhibited rapid plasma and tissue elimination, improved tolerability in preclinical models, and maintained potency comparable to the most advanced lipids.
In recent years, RNA interference (RNAi) therapeutics, most notably with lipid nanoparticle-based delivery systems, have advanced into human clinical trials. The results from these early clinical trials suggest that lipid nanoparticles (LNPs), and the novel ionizable lipids that comprise them, will be important materials in this emerging field of medicine. A persistent theme in the use of materials for biomedical applications has been the incorporation of biodegradability as a means to improve biocompatibility and/or to facilitate elimination. Therefore, the aim of this work was to further advance the LNP platform through the development of novel, next-generation lipids that combine the excellent potency of the most advanced lipids currently available with biodegradable functionality. As a representative example of this novel class of biodegradable lipids, the lipid evaluated in this work displays rapid elimination from plasma and tissues, substantially improved tolerability in preclinical studies, while maintaining in vivo potency on par with that of the most advanced lipids currently available. In recent years, RNA interference (RNAi) therapeutics, most notably with lipid nanoparticle-based delivery systems, have advanced into human clinical trials. The results from these early clinical trials suggest that lipid nanoparticles (LNPs), and the novel ionizable lipids that comprise them, will be important materials in this emerging field of medicine. A persistent theme in the use of materials for biomedical applications has been the incorporation of biodegradability as a means to improve biocompatibility and/or to facilitate elimination. Therefore, the aim of this work was to further advance the LNP platform through the development of novel, next-generation lipids that combine the excellent potency of the most advanced lipids currently available with biodegradable functionality. As a representative example of this novel class of biogenerative lipids, the lipid evaluated in this work displays rapid elimination from plasma and tissues, substantially improved tolerability in preclinical studies, while maintaining in vivo potency on par with that of the most advanced lipids currently available.
16
Rational design of cationic lipids for siRNA delivery
Sean C. Semple, Akin Akinc, Jianxin Chen et al. · Nature Biotechnology · 2010 · 1.8K citations
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
Akin Akinc, William Querbes, Soma De et al. · Molecular Therapy · 2010 · 1.2K citations · Full text